By Fineline Cube Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.
Regulatory Development
| Item | Detail |
|---|---|
| Company | Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) |
| Product | Efperepoetin alfa – recombinant EPO-Fc fusion protein |
| Indication | Anemia due to chronic kidney disease (CKD) in adult dialysis patients on erythropoietin therapy |
| Regulatory Action | Voluntary withdrawal of drug registration application |
| Reason for Withdrawal | Need for further improvement of application dossiers |
| Market Status | No similar EPO-Fc fusion product approved in China |
| Technology Platform | Recombinant fusion protein with extended half-life properties |
Product Profile & Therapeutic Rationale
- Molecular Structure: Recombinant fusion protein combining human erythropoietin (EPO) with Fc fragment of human IgG2, designed to extend serum half-life through neonatal Fc receptor (FcRn) recycling mechanism
- Therapeutic Advantage: Potential for less frequent dosing compared to conventional erythropoiesis-stimulating agents (ESAs), improving patient convenience and compliance in chronic dialysis settings
- Target Population: Adult CKD patients on dialysis currently receiving erythropoietin therapy, representing a significant portion of China’s estimated 300,000+ dialysis patients
- Competitive Landscape: While EPO-Fc fusion proteins like efapegotin alfa (marketed as Retacrit® in some regions) exist globally, China lacks approved products in this extended-half-life ESA category
Market Context & Strategic Implications
The Chinese anemia management market in CKD represents a substantial commercial opportunity, with erythropoiesis-stimulating agents (ESAs) generating annual sales exceeding RMB 2 billion. Current treatment options primarily consist of short-acting recombinant human EPO requiring multiple weekly injections, creating significant burden for dialysis patients who already undergo frequent clinic visits.
Extended-half-life ESAs have demonstrated superior pharmacokinetic profiles and reduced dosing frequency in international markets, but regulatory approval in China has been limited by stringent dossier requirements and comprehensive clinical data expectations from the NMPA.
Key strategic considerations for Buchang:
- Regulatory Strategy: Withdrawal suggests incomplete or insufficient clinical/non-clinical data packages rather than safety or efficacy concerns
- Development Timeline: Re-submission likely requires additional studies or enhanced documentation, potentially delaying market entry by 12-24 months
- Competitive Positioning: First-mover advantage remains available given absence of approved competitors in China’s EPO-Fc segment
- Portfolio Impact: Represents setback in Buchang’s biologics diversification strategy beyond traditional Chinese medicine products
Next Steps & Outlook
- Dossier Enhancement: Comprehensive review and strengthening of clinical, non-clinical, and CMC (Chemistry, Manufacturing, Controls) documentation
- Regulatory Resubmission: Target re-filing once dossier improvements are completed, potentially under enhanced communication protocols with NMPA
- Clinical Development: Possible requirement for additional comparative studies or pharmacokinetic/pharmacodynamic data to support extended dosing claims
- Manufacturing Validation: Enhanced process validation and quality control documentation to meet NMPA biologics standards
- Market Preparation: Continued engagement with key opinion leaders and dialysis centers to maintain awareness of product potential
Industry Context
This withdrawal reflects the increasingly stringent regulatory environment for biologics in China, where the NMPA has implemented comprehensive review standards aligned with international guidelines. Companies developing biosimilars and novel biologics face heightened expectations for robust clinical data, comprehensive safety profiles, and manufacturing excellence.
The extended-half-life ESA market remains attractive despite regulatory challenges, with global products demonstrating 20-30% market share in developed markets and premium pricing justified by improved patient outcomes and reduced healthcare resource utilization.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory resubmission timelines, development plans, and market opportunities. Actual results may differ due to risks including regulatory requirements, competitive developments, clinical data requirements, and market dynamics.-Fineline Info & Tech